While our comparative analysis of cytotoxic CD4+ T cells across cancer and non-cancer contexts reveals some conserved effector cytolytic functions (and MHC class II-dependent recognition), as well as overlap in master TFs associated with this CD4+ T cell state, the available evidence also highlights at least two distinct challenges for their therapeutic targeting. This evidence concerns the gene CD4 and cancer.